We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Shortages and supply disruptions (17)
- Safety monitoring and information (121)
- Compliance and enforcement (32)
- Import and export (28)
- Sunscreens (7)
- Advertising (6)
- COVID-19 (5)
- Labelling and packaging (4)
- Weight loss products (4)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
1046 result(s) found, displaying 576 to 600
-
Safety alertsUpdate - adverse event monitoring
-
-
Market actionsRecall for product correction - fire risk from faulty component
-
Market actionsRecall for product correction - fire risk from faulty component
-
Market actionsThe following medicines (with brand names in brackets) should be returned to a pharmacy: alprazolam (Xanax), cabergoline (Dostinex and Cabaser), mefanamic acid (Ponstan), methotrexate (Methoblastin) and triazolam (Halcion)
-
Market actionsRecall - bottles supplied without child-resistant caps
-
Market actionsRecall for product correction - risk of sparking or fire due to damaged or cut wire
-
-
Market actionsRecall - counterfeit products may have defects and not be effective
-
Market actionsRecall for product correction - potential for insulin to not be delivered as intended
-
-
-
-
-
-
-
Market actionsUpdate - recall for product correction - advertisements published to inform all affected users
-
-
-
Market actionsRecall - incorrect contact lenses supplied to some consumers
-
Market actionsRecall - risk of adverse events due to potential dilution
-
-
-
Safety alertsSafety advisory
-
Safety alertsSafety alert - higher than expected revision rate when used without patella resurfacing